CIK 0001770069 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
MapLight Therapeutics, Inc.
Sign in to watch- Ticker
- MPLT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832163243
- Phone
- 650-839-4360
- Business address
- 800 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
- Former names
- Alvarado Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,256,232
- in 7 filings, $193K under 10b5-1 plans
Net −$1,256,232. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Kroeger Christopher A. −$595K Chief Executive Officer sold 6% of stake
- Hanson Kristopher −$266K General Counsel sold 17% of stake
- Foff Erin Pennock −$124K Chief Medical Officer sold 5% of stake
- Kreitzer Anatol −$96K Chief Discovery Officer sold 7% of stake
- Lillie James Woodruff −$93K Chief Scientific Officer sold 5% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-04 | Setia Vishwas Chief Financial Officer | Sale 10b5-1 | −8,989 | $28.28 | $254K | 378,835 |
| 2026-05-04 | Setia Vishwas Chief Financial Officer | Sale 10b5-1 | −325 | $29.56 | $10K | 378,510 |
| 2026-05-04 | Setia Vishwas Chief Financial Officer | Sale 10b5-1 | −787 | $30.12 | $24K | 377,723 |
| 2026-05-04 | Foff Erin Pennock Chief Medical Officer | Sale 10b5-1 | −9,180 | $27.50 | $252K | 391,597 |
| 2026-05-04 | Foff Erin Pennock Chief Medical Officer | Sale 10b5-1 | −5,460 | $28.37 | $155K | 386,137 |
| 2026-05-04 | Foff Erin Pennock Chief Medical Officer | Sale 10b5-1 | −312 | $29.56 | $9K | 385,825 |
| 2026-05-04 | Foff Erin Pennock Chief Medical Officer | Sale 10b5-1 | −700 | $30.08 | $21K | 385,125 |
| 2026-05-04 | Hanson Kristopher General Counsel | Sale 10b5-1 | −9,030 | $27.50 | $248K | 181,135 |
| 2026-05-04 | Hanson Kristopher General Counsel | Sale 10b5-1 | −3,908 | $28.29 | $111K | 177,227 |
| 2026-05-04 | Hanson Kristopher General Counsel | Sale 10b5-1 | −296 | $29.56 | $9K | 176,931 |
| 2026-05-04 | Hanson Kristopher General Counsel | Sale 10b5-1 | −683 | $30.08 | $21K | 176,248 |
| 2026-05-04 | Lillie James Woodruff Chief Scientific Officer | Sale 10b5-1 | −9,250 | $27.50 | $254K | 285,907 |
| 2026-05-04 | Lillie James Woodruff Chief Scientific Officer | Sale 10b5-1 | −5,526 | $28.37 | $157K | 280,381 |
| 2026-05-04 | Lillie James Woodruff Chief Scientific Officer | Sale 10b5-1 | −320 | $29.56 | $9K | 280,061 |
| 2026-05-04 | Lillie James Woodruff Chief Scientific Officer | Sale 10b5-1 | −705 | $30.08 | $21K | 279,356 |
| 2026-05-04 | Kroeger Christopher A. Chief Executive Officer | Sale 10b5-1 | −9,136 | $27.50 | $251K | 1,621,428 |
| 2026-05-04 | Kroeger Christopher A. Chief Executive Officer | Sale 10b5-1 | −5,427 | $28.37 | $154K | 1,616,001 |
| 2026-05-04 | Kroeger Christopher A. Chief Executive Officer | Sale 10b5-1 | −311 | $29.56 | $9K | 1,615,690 |
| 2026-05-04 | Kroeger Christopher A. Chief Executive Officer | Sale 10b5-1 | −697 | $30.08 | $21K | 1,614,993 |
| 2026-04-28 | GILLIS JONATHAN CAAO and PAO | Sale 10b5-1 | −17,235 | $30.33 | $523K | 181,919 |
Page 7 of 12 · 239 trades